Antidpressant, Fluvoxamine, Reduces Severe Covid-19 Disease, Study FindsBy Radiant Health
Published: October 31, 2021
A new study published in Lancet Global Health found that a 10-day course of fluvoxamine (brand name Luvox), a drug commonly prescribed for depression and obsessive-compulsive disorder, significantly reduced the need for hospitalization by 66% and cut deaths by 91% in people at high risk of severe covid-19 disease. A full treatment course with fluvoxamine costs about $10 compared to $700 for a 5-day treatment course with Merck’s antiviral pill, molnupiravir. The expert panel that develops US Covid-19 treatment guidelines has been briefed on the study data and could decide soon about recommending fluvoxamine as an early treatment.
Like what you're reading? Sign up for our free newsletter and never miss a post! Plus get a FREE digital version of our Issue No.10 with sign up.
- Pfizer’s Antiviral Pill is Very Effective - May 15, 2022
- Spain Considers Three Days Off for Menstrual Pain - May 15, 2022
- Moderna Requests Approval for its Children’s Vaccine - May 15, 2022
- Routine Colonoscopies Should Start at Age 45 - May 15, 2022
- Anti-inflammatory Drugs May Do More Harm Than Good - May 15, 2022
- Some People Die from a Happy Heart - May 8, 2022
- Johnson & Johnson Vaccine Can Cause Serious Blood Clots - May 8, 2022
- Omicron Variants Spreading Quickly - May 8, 2022
- Roe V. Wade Will Likely Be Overturned - May 8, 2022
- Menthol Cigarette Ban Will Benefit the Black Community - April 30, 2022